EA201691095A1 - Мутантные фрагменты ospa и связанные с ними способы и применение - Google Patents

Мутантные фрагменты ospa и связанные с ними способы и применение

Info

Publication number
EA201691095A1
EA201691095A1 EA201691095A EA201691095A EA201691095A1 EA 201691095 A1 EA201691095 A1 EA 201691095A1 EA 201691095 A EA201691095 A EA 201691095A EA 201691095 A EA201691095 A EA 201691095A EA 201691095 A1 EA201691095 A1 EA 201691095A1
Authority
EA
Eurasian Patent Office
Prior art keywords
applications
related methods
ospa
mutant fragments
borrelia infection
Prior art date
Application number
EA201691095A
Other languages
English (en)
Other versions
EA034554B1 (ru
Inventor
Урбан Лундберг
Вольфганг Шюлер
Original Assignee
Валнева Аустриа Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Валнева Аустриа Гмбх filed Critical Валнева Аустриа Гмбх
Publication of EA201691095A1 publication Critical patent/EA201691095A1/ru
Publication of EA034554B1 publication Critical patent/EA034554B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1207—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Изобретение относится к композициям и способам для профилактики и лечения инфекции Borrelia. В частности, настоящее изобретение относится к полипептиду, содержащему гибридный С-концевой фрагмент внешнего поверхностного белка A (OspA), нуклеиновой кислоте, кодирующей его, антителу, специфически связывающему его, фармацевтической композиции (в частности, для применения в качестве лекарственного средства или в способе лечения или профилактики инфекции Borrelia), содержащей полипептид и/или нуклеиновую кислоту, и/или антитело, способу лечения или профилактики инфекции Borrelia, а также способу иммунизации субъекта.
EA201691095A 2014-01-09 2015-01-09 МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ EA034554B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14150682 2014-01-09
PCT/EP2015/050365 WO2015104396A1 (en) 2014-01-09 2015-01-09 Mutant fragments of ospa and methods and uses relating thereto

Publications (2)

Publication Number Publication Date
EA201691095A1 true EA201691095A1 (ru) 2017-03-31
EA034554B1 EA034554B1 (ru) 2020-02-19

Family

ID=49917594

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691095A EA034554B1 (ru) 2014-01-09 2015-01-09 МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ

Country Status (24)

Country Link
US (4) US9975927B2 (ru)
EP (2) EP3092246B1 (ru)
JP (1) JP6505110B2 (ru)
KR (1) KR102460165B1 (ru)
CN (1) CN105980398B (ru)
AU (1) AU2015205520B2 (ru)
BR (2) BR122023024315A2 (ru)
CA (1) CA2931110A1 (ru)
CY (1) CY1121734T1 (ru)
DK (1) DK3092246T3 (ru)
EA (1) EA034554B1 (ru)
ES (1) ES2740985T3 (ru)
HR (1) HRP20191086T1 (ru)
HU (1) HUE043779T2 (ru)
LT (1) LT3092246T (ru)
MX (1) MX369195B (ru)
NZ (1) NZ721015A (ru)
PL (1) PL3092246T3 (ru)
PT (1) PT3092246T (ru)
RS (1) RS59075B1 (ru)
SI (1) SI3092246T1 (ru)
TR (1) TR201910117T4 (ru)
WO (1) WO2015104396A1 (ru)
ZA (1) ZA201602690B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
CN105980398B (zh) * 2014-01-09 2019-11-26 瓦尔尼瓦奥地利有限责任公司 OspA的突变片段以及其相关方法和用途
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
US20230398210A1 (en) * 2020-04-09 2023-12-14 Valneva Austria Gmbh Improvements in vaccine formulations for medical use
JP2023522170A (ja) 2020-04-09 2023-05-29 バルネバ オーストリア ゲーエムベーハ― 医学的使用のための３つのＯｓｐＡ融合タンパク質を含む組成物
WO2023212520A1 (en) 2022-04-25 2023-11-02 Pfizer Inc. Compositions and methods for eliciting an immune response protective against lyme disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
US6248562B1 (en) * 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
DK1311540T3 (da) 2000-08-18 2008-04-28 Brookhaven Sciences Ass Llc Ændret OspA af Borrelia Burgdorferi
UA89481C2 (ru) 2003-09-30 2010-02-10 Центокор, Инк. Эритропоэтиновые миметические шарнирно-сердцевинные миметитела человека, композиции, способы и применение
WO2008031133A2 (en) * 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
PL2486938T3 (pl) 2006-09-26 2018-08-31 Infectious Disease Research Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
AU2011252850B2 (en) 2010-05-14 2016-03-17 Baxalta GmbH OspA chimeras and use thereof in vaccines
TWI507413B (zh) 2010-11-15 2015-11-11 Nat Health Research Institutes 脂質化多抗原表位疫苗
TW201221642A (en) 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
CN105980398B (zh) * 2014-01-09 2019-11-26 瓦尔尼瓦奥地利有限责任公司 OspA的突变片段以及其相关方法和用途
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto

Also Published As

Publication number Publication date
AU2015205520A1 (en) 2016-06-30
US9975927B2 (en) 2018-05-22
SI3092246T1 (sl) 2019-08-30
JP2017503792A (ja) 2017-02-02
MX2016008989A (es) 2016-10-04
EP3092246A1 (en) 2016-11-16
KR102460165B1 (ko) 2022-10-28
CA2931110A1 (en) 2015-07-16
US20210054032A1 (en) 2021-02-25
MX369195B (es) 2019-10-31
BR112016015678A2 (pt) 2017-10-03
ES2740985T3 (es) 2020-02-07
CN105980398A (zh) 2016-09-28
US20230322869A1 (en) 2023-10-12
HRP20191086T1 (hr) 2019-11-01
DK3092246T3 (da) 2019-07-15
EP3092246B1 (en) 2019-06-05
PT3092246T (pt) 2019-07-19
TR201910117T4 (tr) 2019-07-22
BR112016015678B1 (pt) 2024-02-06
KR20160102993A (ko) 2016-08-31
HUE043779T2 (hu) 2019-09-30
LT3092246T (lt) 2019-07-10
US20160333056A1 (en) 2016-11-17
JP6505110B2 (ja) 2019-04-24
US11572392B2 (en) 2023-02-07
US20180362593A1 (en) 2018-12-20
CN105980398B (zh) 2019-11-26
EA034554B1 (ru) 2020-02-19
AU2015205520B2 (en) 2017-06-29
PL3092246T3 (pl) 2019-09-30
RS59075B1 (sr) 2019-09-30
US10766931B2 (en) 2020-09-08
WO2015104396A1 (en) 2015-07-16
CY1121734T1 (el) 2020-07-31
NZ721015A (en) 2017-09-29
BR122023024315A2 (pt) 2023-12-26
EP3564257A1 (en) 2019-11-06
ZA201602690B (en) 2017-09-27

Similar Documents

Publication Publication Date Title
EA201590162A1 (ru) МУТАНТНЫЕ ФРАГМЕНТЫ OspA И СВЯЗАННЫЕ С НИМИ СПОСОБЫ И ПРИМЕНЕНИЕ
EA201691095A1 (ru) Мутантные фрагменты ospa и связанные с ними способы и применение
MD4716B1 (ru) Антитела анти-LAG3 и антигенсвязывающие фрагменты
MX2018007406A (es) Anticuerpos anti-lag3 y fragmentos de enlace al antigeno.
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
JOP20160131B1 (ar) الأجسام المضادة للعامل xi وطرق الاستخدام
MX2015017045A (es) Inhibidores de bromodominio biciclicos novedosos.
MX2014009909A (es) Acido nucleico que comprende o codifica un tallo-bucle de histona y una secuencia poli(a) o una señal de poliadenilacion para incrementar la expresion de un antigeno tumoral codificado.
EA201690159A1 (ru) Способы и композиции для лечения рака
MY178445A (en) Novel antibody binding to tfpi and composition comprising the same
WO2015067755A3 (en) Novel methods and antibodies for treating coagulapathy
EA201891141A1 (ru) Новые антиангиогенные слитые полипептиды
WO2015187521A3 (en) Anti-blys antibodies
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
TN2018000180A1 (en) Polypeptides inhibiting cd40l
PH12020552222A1 (en) Immunodominant proteins and fragments in multiple sclerosis
EA201491668A1 (ru) Вакцины и способы для лечения болезни лайма у собак
EA202092121A1 (ru) Антитела против cd73 и их применения
EA201790403A1 (ru) Антитела против lag3 и антигенсвязывающие фрагменты
EA201992057A1 (ru) Персонализированная платформа для идентификации иммуногенного пептида
EA201990927A1 (ru) Антитела против lag-3 и способы их применения